Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
Targeted and immunotherapy regimens have revolutionized the treatment of advanced melanoma patients. Despite this, only a subset of patients respond durably. Recently, combination strategies of BRAF/MEK inhibitors with immune checkpoint inhibitor monotherapy (α-CTLA-4 or α-PD-1) have increased the r...
Enregistré dans:
Auteurs principaux: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Taylor & Francis Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e6152b9f5495402183474ea2dacf7022 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|